Wugen
St Louis
About Wugen
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $287.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2025)
- Website: wugen.com
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/wugen-81663 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.